Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Treatment With PEG-Intron and Rebetol in Genotype 1 HCV Slow Responders
NCT00265395Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2004
- Primary completion
- May 2008
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b, ribavirin in hepatitis C (HCV), sponsored by Merck & Co.. Started Dec 2004; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00265395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265395.